Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

8.3K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
8.3K
Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

6.5K
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
6.5K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

10.4K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.4K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

3.4K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

7.9K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of small-molecule HSF1 amplifiers by high content screening in protection of cells from stress induced injury.

Biochemical and biophysical research communications·2009
Same author

Nanowire transformation by size-dependent cation exchange reactions.

Nano letters·2009
Same author

Effect of haishengsu as an adjunct therapy for patients with advanced renal cell cancer: a randomized and placebo-controlled clinical trial.

Journal of alternative and complementary medicine (New York, N.Y.)·2009
Same author

Identification of inhibitors of HSF1 functional activity by high-content target-based screening.

Journal of biomolecular screening·2009
Same author

Antitumor effects of targeting hTERT lentivirus-mediated RNA interference against KB cell lines.

Oncology research·2009
Same author

Characteristics of emissive spectrum and the removal of nitric oxide in N2/02/NO plasma with argon additive.

Journal of environmental sciences (China)·2009

Related Experiment Video

Updated: Mar 29, 2026

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.9K

Interplay Between Poly(ADP-ribosyl)ation and Specific Inner Cellular Events That Suggest Combination Strategies for

Lingwen Xu1,2, Xiangyu Kong1,2, Bin Zhang1,2

  • 1Institute of Chemical Drugs, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China.

Pharmaceutics
|March 28, 2026
PubMed
Summary

PARP inhibitors (PARPi) are vital for cancer therapy but face resistance. Combination strategies targeting DNA damage response (DDR) pathways are key to overcoming resistance and improving durable cancer control.

Keywords:
DNA damage responsePARP inhibitorscombination therapyhomologous recombination deficiencyresistancesynthetic lethality

More Related Videos

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.7K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.7K

Related Experiment Videos

Last Updated: Mar 29, 2026

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.9K
Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.7K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.7K

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Therapeutic resistance is a major challenge in cancer treatment.
  • The DNA damage response (DDR) network plays a critical role in cancer progression and therapeutic resistance.
  • Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) are effective against tumors with homologous recombination deficiency (HRD), but resistance is common.

Purpose of the Study:

  • To review the mechanisms of PARPi action and resistance.
  • To explore emerging combination strategies for overcoming PARPi resistance.
  • To highlight the importance of understanding DDR regulation for advancing precision cancer therapy.

Main Methods:

  • Review of molecular mechanisms of PARPi action.
  • Analysis of established and emerging PARPi resistance pathways.
  • Summary of preclinical and clinical data on combination therapies involving PARPi.

Main Results:

  • PARPi resistance mechanisms include HR restoration, replication fork protection, RAD51-mediated strand invasion, and metabolic reprogramming.
  • Combination therapies (e.g., with HDAC inhibitors, CDK inhibitors, immune checkpoint blockade, radiation) enhance PARPi efficacy.
  • These combinations target DNA repair pathways and the tumor immune microenvironment.

Conclusions:

  • Overcoming PARPi resistance requires a comprehensive understanding of DDR network regulation.
  • Rationally designed combination regimens are essential for improving adaptive, precision-based cancer therapy.
  • Further research into coordinated DDR regulation will facilitate the development of more effective cancer treatments.